Novel Neuroprotective Mechanisms of Memantine: Increase in Neurotrophic Factor Release from Astroglia and Anti-Inflammation by Preventing Microglial Activation

Memantine shows clinically relevant efficacy in patients with Alzheimer's disease and Parkinson's disease. Most in vivo and in vitro studies attribute the neuroprotective effects of memantine to the blockade of N-methyl-D-aspartate (NMDA) receptor on neurons. However, it cannot be excluded that mechanisms other than NMDA receptor blockade may contribute to the neuroprotective effects of this compound. To address this question, primary midbrain neuron–glia cultures and reconstituted cultures were used, and lipopolysaccharide (LPS), an endotoxin from bacteria, was used to produce inflammation-mediated dopaminergic (DA) neuronal death. Here, we show that memantine exerted both potent neurotrophic and neuroprotective effects on DA neurons in rat neuron–glia cultures. The neurotrophic effect of memantine was glia dependent, as memantine failed to show any positive effect on DA neurons in neuron-enriched cultures. More specifically, it seems to be that astroglia, not microglia, are the source of the memantine-elicited neurotrophic effects through the increased production of glial cell line-derived neurotrophic factor (GDNF). Mechanistic studies showed that GDNF upregulation was associated with histone hyperacetylation by inhibiting the cellular histone deacetylase activity. In addition, memantine also displays neuroprotective effects against LPS-induced DA neuronal damage through its inhibition of microglia activation showed by both OX-42 immunostaining and reduction of pro-inflammatory factor production, such as extracellular superoxide anion, intracellular reactive oxygen species, nitric oxide, prostaglandin E2, and tumor necrosis factor-α. These results suggest that the neuroprotective effects of memantine shown in our cell culture studies are mediated in part through alternative novel mechanisms by reducing microglia-associated inflammation and by stimulating neurotrophic factor release from astroglia.

[1]  H. Ushijima,et al.  HIV-1 gp120 and NMDA induce protein kinase C translocation differentially in rat primary neuronal cultures. , 1993, Journal of Acquired Immune Deficiency Syndromes.

[2]  Yue Huang,et al.  Genetic contributions to Parkinson's disease , 2004, Brain Research Reviews.

[3]  J. Rogers,et al.  Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder? , 2007, International review of neurobiology.

[4]  M. Vila,et al.  Pathogenic role of glial cells in Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.

[5]  R. Tennant,et al.  12-O-Tetradecanoylphorbol-13-acetate and UV Radiation-induced Nucleoside Diphosphate Protein Kinase B Mediates Neoplastic Transformation of Epidermal Cells* , 2004, Journal of Biological Chemistry.

[6]  J. McGinty,et al.  l‐trans‐Pyrrolidine‐2,4‐Dicarboxylic Acid‐Evoked Striatal Glutamate Levels Are Attenuated by Calcium Reduction, Tetrodotoxin, and Glutamate Receptor Blockade , 1997, Journal of neurochemistry.

[7]  Bin Liu,et al.  NADPH Oxidase Mediates Lipopolysaccharide-induced Neurotoxicity and Proinflammatory Gene Expression in Activated Microglia* , 2004, Journal of Biological Chemistry.

[8]  S. Lipton,et al.  The chemical biology of clinically tolerated NMDA receptor antagonists , 2006, Journal of neurochemistry.

[9]  M. Merello,et al.  Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. , 1999, Clinical neuropharmacology.

[10]  M. Weller,et al.  MK-801 and memantine protect cultured neurons from glutamate toxicity induced by glutamate carboxypeptidase-mediated cleavage of methotrexate. , 1993, European journal of pharmacology.

[11]  B. Liu,et al.  Inhibition by Naloxone Stereoisomers of β-Amyloid Peptide (1–42)-induced Superoxide Production in Microglia and Degeneration of Cortical and Mesencephalic Neurons , 2002, Journal of Pharmacology and Experimental Therapeutics.

[12]  Steven A. Johnson,et al.  BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease , 1991, Neuron.

[13]  Masahiko Watanabe,et al.  Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. , 1997, Science.

[14]  B. Liu,et al.  Distinct Role for Microglia in Rotenone-Induced Degeneration of Dopaminergic Neurons , 2002, The Journal of Neuroscience.

[15]  P. Marks,et al.  Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors , 1999, Nature.

[16]  F. Crews,et al.  Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration , 2007, Glia.

[17]  C. Darlington Astrocytes as targets for neuroprotective drugs. , 2005, Current opinion in investigational drugs.

[18]  Chris G. Parsons,et al.  Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse , 2007, Neuropharmacology.

[19]  Bin Liu,et al.  Role of Microglia in Inflammation-Mediated Neurodegenerative Diseases: Mechanisms and Strategies for Therapeutic Intervention , 2003, Journal of Pharmacology and Experimental Therapeutics.

[20]  B. Liu,et al.  Primary rat mesencephalic neuron-glia, neuron-enriched, microglia-enriched, and astroglia-enriched cultures. , 2003, Methods in molecular medicine.

[21]  L. Buée,et al.  Neurotrophic factors in Alzheimer’s disease: role of axonal transport , 2008, Genes, brain, and behavior.

[22]  M. Caraglia,et al.  Acetylation of proteins as novel target for antitumor therapy: Review article , 2004, Amino Acids.

[23]  S. Lipton Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond , 2006, Nature Reviews Drug Discovery.

[24]  M. Murer,et al.  Brain-derived neurotrophic factor in the control human brain, and in Alzheimer’s disease and Parkinson’s disease , 2001, Progress in Neurobiology.

[25]  C. Parsons,et al.  The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence , 2003, International journal of geriatric psychiatry.

[26]  Bin Liu,et al.  Microglia enhance β‐amyloid peptide‐induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species , 2002 .

[27]  G. Li,et al.  Nanometer size diesel exhaust particles are selectively toxic to dopaminergic neurons: the role of microglia, phagocytosis, and NADPH oxidase , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  D. Chuang,et al.  Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. , 2008, The international journal of neuropsychopharmacology.

[29]  M. Block,et al.  Microglia-mediated neurotoxicity: uncovering the molecular mechanisms , 2007, Nature Reviews Neuroscience.

[30]  Timothy Sendera,et al.  Clinicopathological findings following intraventricular glial‐derived neurotrophic factor treatment in a patient with Parkinson's disease , 1999, Annals of neurology.

[31]  P. Gean,et al.  Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes , 2006, Molecular Psychiatry.

[32]  C. Barnes,et al.  Memantine protects against LPS-induced neuroinflammation, restores behaviorally-induced gene expression and spatial learning in the rat , 2006, Neuroscience.

[33]  R. Dempsey,et al.  Protective Effects of Memantine Against Ischemia-Reperfusion Injury in Spontaneously Hypertensive Rats , 1999, Acta Neurochirurgica.

[34]  T. Jay,et al.  Excitotoxicity in neurological disorders — the glutamate paradox , 2000, International Journal of Developmental Neuroscience.

[35]  Leif Hertz,et al.  Astrocytic control of glutamatergic activity: astrocytes as stars of the show , 2004, Trends in Neurosciences.

[36]  G. Wilcock,et al.  A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500) , 2002, International clinical psychopharmacology.

[37]  R. Arantes,et al.  A Role for Synaptotagmin VII-Regulated Exocytosis of Lysosomes in Neurite Outgrowth from Primary Sympathetic Neurons , 2006, The Journal of Neuroscience.

[38]  S. Lipton Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. , 2007, Current drug targets.

[39]  L. V. Van Eldik,et al.  Glia as a Therapeutic Target: Selective Suppression of Human Amyloid-β-Induced Upregulation of Brain Proinflammatory Cytokine Production Attenuates Neurodegeneration , 2006, The Journal of Neuroscience.

[40]  P. Toth,et al.  In vitro galantamine-memantine co-application: Mechanism of beneficial action , 2006, Neuropharmacology.

[41]  L. V. Van Eldik,et al.  P4-428 Glia as a therapeutic target: Selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration , 2006, Alzheimer's & Dementia.

[42]  M. Weller,et al.  NMDA receptor-mediated glutamate toxicity of cultured cerebellar, cortical and mesencephalic neurons: neuroprotective properties of amantadine and memantine , 1993, Brain Research.

[43]  M. Block,et al.  Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism , 2005, Progress in Neurobiology.

[44]  J. Roh,et al.  Memantine Reduces Hematoma Expansion in Experimental Intracerebral Hemorrhage, Resulting in Functional Improvement , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[45]  C. Parsons,et al.  Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. , 2006, Behavioural pharmacology.

[46]  S. Barger,et al.  Glutamate release from activated microglia requires the oxidative burst and lipid peroxidation , 2007, Journal of neurochemistry.

[47]  Tony Wyss-Coray,et al.  Inflammation in Alzheimer disease: driving force, bystander or beneficial response? , 2006, Nature Medicine.

[48]  H. Ushijima,et al.  Cytoprotective effect of NMDA receptor antagonists on prion protein (PrionSc)-induced toxicity in rat cortical cell cultures. , 1993, European journal of pharmacology.

[49]  J. Jankovic,et al.  Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD , 2003, Neurology.

[50]  J. Lile,et al.  GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. , 1993, Science.

[51]  W. Danysz,et al.  The cytotoxicity of chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenase-2 inhibition , 2000, Experimental Brain Research.

[52]  Akio Suzumura,et al.  Neuritic Beading Induced by Activated Microglia Is an Early Feature of Neuronal Dysfunction Toward Neuronal Death by Inhibition of Mitochondrial Respiration and Axonal Transport* , 2005, Journal of Biological Chemistry.

[53]  J. Nutt,et al.  Treatment of Parkinson’s disease with trophic factors , 2008, Neurotherapeutics.

[54]  P. Bickford,et al.  Brain-Derived Neurotrophic Factor Is Required for the Establishment of the Proper Number of Dopaminergic Neurons in the Substantia Nigra Pars Compacta , 2005, The Journal of Neuroscience.

[55]  Bin Liu,et al.  Microglia enhance beta-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species. , 2002, Journal of neurochemistry.

[56]  P. Gean,et al.  Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity , 2007, Neuroscience.

[57]  E. Hermans,et al.  Specific regulation of rat glial cell line‐derived neurotrophic factor gene expression by riluzole in C6 glioma cells , 2006, Journal of neurochemistry.

[58]  E. Hermans,et al.  Amantadine and memantine induce the expression of the glial cell line-derived neurotrophic factor in C6 glioma cells , 2006, Neuroscience Letters.

[59]  M. Riepe,et al.  Memantine in Moderate-to-severe Alzheimer's Disease , 2006 .

[60]  Melina V Jones,et al.  Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: Protection by memantine , 2000, Annals of neurology.